EntreMed, Inc. Commences Clinical Trial For MKC-1 In Lung Cancer Patients

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a multi-center study with its drug candidate, MKC-1, in non-small cell lung cancer (NSCLC) patients. The lead institution for this Phase 1/2, open label, dose escalation study will be the Indiana University Cancer Center in Indianapolis, Indiana. Nasser H. Hanna, M.D., Assistant Professor, Department of Medicine, Division of Hematology/Oncology at IUCCI, will serve as Principal Investigator. MKC-1 is being evaluated currently in Phase 1 and 2 clinical studies against breast cancer and in patients with leukemia.